|
May 9
|
NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
Apr 30
|
NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June
|
|
Apr 23
|
NRBO: First Patient Dosed in Phase 1 Trial of DA-1726 for the Treatment of Obesity…
|
|
Apr 17
|
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
|
|
Apr 1
|
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
|
|
Mar 28
|
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
|
|
Mar 13
|
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
|
|
Mar 4
|
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
|
|
Feb 29
|
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
|
|
Jan 9
|
NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
|
|
Jan 2
|
NeuroBo to Participate in Industry and Investor Conferences in January
|
|
Dec 28
|
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
|
|
Dec 19
|
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
|
|
Dec 1
|
NeuroBo to Participate in Investor Conferences in December
|
|
May 2
|
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH
|